Lidokain Aguettant (Lidocaine Hydrochloride)

Lidocaine hydrochloride blocks voltage‑gated sodium channels on nerve membranes, preventing the initiation and propagation of action potentials. This inhibition stops nerve signals from reaching the brain, producing a reversible loss of sensation in the area where it is administered.

The dose of Lidokain Aguettant is determined by the prescribing clinician based on the type of procedure, the size of the treatment area, patient weight and overall health. Only a qualified healthcare professional should calculate and administer the appropriate amount.

Safety data for lidocaine hydrochloride in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under the guidance of a qualified healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Lidocaine offers a rapid onset (1–3 minutes) and moderate duration (30–120 minutes), making it suitable for short procedures. Compared with longer‑acting agents such as bupivacaine, lidocaine provides quicker recovery but a shorter analgesic window, which can be advantageous when fast return of sensation is desired.

Store the product at ambient temperature, preferably below 25 °C, in its original sealed container. Protect it from direct sunlight, moisture and extreme temperatures to maintain sterility and potency.

The solution is administered by infiltration, intradermal or subcutaneous injection. The clinician injects the drug directly into the tissue surrounding the target area, often after aspirating to ensure the needle is not within a blood vessel.

Serious risks include severe allergic reactions (anaphylaxis), cardiac arrhythmias such as ventricular tachycardia, and central nervous system toxicity that can lead to seizures or loss of consciousness. Immediate medical attention is required if any of these symptoms occur.

Patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics, those with severe heart block, uncontrolled arrhythmias, or certain metabolic disorders should avoid using this product. The prescribing clinician must assess each patient’s medical history before administration.